80,849 Shares in Emergent Biosolutions Inc. $EBS Purchased by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC acquired a new stake in shares of Emergent Biosolutions Inc. (NYSE:EBS) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 80,849 shares of the biopharmaceutical company’s stock, valued at approximately $713,000.

A number of other hedge funds have also bought and sold shares of the business. Millennium Management LLC increased its position in shares of Emergent Biosolutions by 68.9% during the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after buying an additional 1,020,582 shares during the period. American Century Companies Inc. lifted its position in Emergent Biosolutions by 3.9% in the 3rd quarter. American Century Companies Inc. now owns 2,382,378 shares of the biopharmaceutical company’s stock worth $21,013,000 after buying an additional 90,216 shares during the last quarter. Geode Capital Management LLC lifted its stake in Emergent Biosolutions by 108.9% in the second quarter. Geode Capital Management LLC now owns 1,278,998 shares of the biopharmaceutical company’s stock worth $8,162,000 after purchasing an additional 666,708 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Emergent Biosolutions by 12.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock worth $5,301,000 after purchasing an additional 121,583 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Emergent Biosolutions by 5.9% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 986,673 shares of the biopharmaceutical company’s stock worth $6,295,000 after acquiring an additional 55,046 shares during the last quarter. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Emergent Biosolutions Stock Down 1.8%

NYSE EBS opened at $8.29 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 2.41 and a current ratio of 5.01. Emergent Biosolutions Inc. has a one year low of $4.02 and a one year high of $14.06. The stock has a 50 day moving average price of $11.29 and a 200-day moving average price of $10.39. The company has a market capitalization of $435.39 million, a P/E ratio of 9.87 and a beta of 2.41.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of $0.11 by ($0.54). The company had revenue of $148.70 million during the quarter, compared to analysts’ expectations of $217.50 million. Emergent Biosolutions had a return on equity of 15.86% and a net margin of 7.08%. As a group, equities analysts predict that Emergent Biosolutions Inc. will post -0.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Weiss Ratings lowered Emergent Biosolutions from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. Wall Street Zen downgraded Emergent Biosolutions from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Emergent Biosolutions in a report on Tuesday, December 16th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $15.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.